ALSO IN THIS ISSUE
When the Patient Loses in Market Access
Lisa Henderson
With so many different rationales for drug pricing and “value” continuing to feed the debate, the market access function in healthcare must clearly tackle these issues—but at what cost to the patient? …Read more
Year in Review: R&D, Regulatory, and Reimbursement Hurdles
Jill Wechsler
Sponsors developed important new therapies amidst ongoing concerns over drug quality and costs …Read more
Who’s Going to Choose Where to Launch a Drug?
Reflector
European Commission working group is looking closely at marketing obligations for centrally authorized products …Read more
|